Akebia Therapeutics Announces that the first patient has received medication in the Phase II trial of Ebribafusp
2026-09-14 20:12:25
According to CoinMeta, Akebia Therapeutics announced that the first patient has received medication in its Phase 2 basket trial for rare complement-mediated kidney diseases, Ebribafusp.
Bullish 0
Bearish 0
Source:Internet
This content is for market information only and does not constitute investment advice.